An anti-MUC1-antibody - Interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells

British Journal of Cancer

Volumn 89, Issue 6, 2003, Pages 1130-1139

  Heuser, C ^a,c   Ganser, M ^a,c   Hombach, A ^a,c   Brand, H ^c   Denton, G ^b   Hanisch, F G ^c   Abken, H ^a,c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antibody cytokine fusion protein; Immunocytokine; Immunotherapy; MUC1; Natural killer cells; scFv; Tumour antigen

Indexed keywords

HYBRID PROTEIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C595; MUCIN 1; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BLOTTING, WESTERN; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CELL DIVISION; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; PEPTIDE FRAGMENTS; PLASMIDS; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC;

EID: 0141955228     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601267     Document Type: Article

References (50)

1. Acres B, Apostolopoulos V, Balloul JM, Wreschner D, Xing PX, Ali-Hadji D, Bizouarne N, Kieny MP, McKenzie IF (2000) MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 48: 588-594
2. Agrawal B, Krantz MJ, Parker J, Longenecker BM (1998) Expression of Muc1 mucin on activated human T cells: implications for a role of muc1 in normal immune regulation. Cancer Res 58: 4079-4081
3. Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF (1997) Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 159: 5211-5218
4. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G, Dogliotti L (1994) Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 30A: 2082-2084
5. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93: 4309-4317
6. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96: 3102-3108
7. Carr-Brendel V, Markovic D, Ferrer K, Smith M, Taylor-Papadimitriou J, Cohen EP (2000) Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1. Cancer Res 60: 2435-2443
8. Denton G, Sekowski M, Spencer DI, Hughes OD, Murray A, Denley H, Tendler SJ, Price MR (1997) Production and characterization of a recombinant anti-MUC1 scFv reactive with human carcinomas. Br J Cancer 76: 614-621
9. Diehl V, Burrichter H, Schaadt M, Kirchner HH, Fonatsch C, Stein H, Gerdes J, Heit W, Ziegler A (1983) Hodgkin's cell lines: characteristics and possible pathogenetic implications. Hematol Oncol 1: 139-147
10. Dixon AR, Price MR, Hand CW, Sibley PE, Selby C, Blamey RW (1993) Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer - a comparison with CA15.3. Br J Cancer 68: 947-949
11. Domenech N, Henderson RA, Finn OJ (1995) Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 155: 4766-4774
12. Engelmann K, Baldus SE, Hanisch F-G (2001) Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1. J Biol Chem 276: 27764-27769
13. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO (2000) Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6: 1693-1701
14. Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D (2000) Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 97: 2715-2718
15. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y (2003) Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 103: 97-100
16. Hanisch FG, Muller S (2000) MUC1: the polymorphic appearance of a human mucin. Glycobiology 10: 439-449
17. He J, Shen D, O'Donnell MA, Chang HR (2002) Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2. Int J Oncol 20: 1305-1311
18. Heukamp LC, van der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, Offringa R (2001) Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. Int J Cancer 91: 385-392
19. Hilkens J, Ligtenberg MJ, Vos HL, Litvinov SV (1992) Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 17: 359-363
20. Hiltbold EM, Ciborowski P, Finn OJ (1998) Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res 58: 5066-5070
21. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, Abken H (1998) An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res 58: 1116-1119
22. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast Jr RC, Finn OJ (1991) Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 51: 2908-2916
23. Jost LM, Kirkwood JM, Whiteside TL (1992) Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods 147: 153-165
24. Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R, Thynne G, McKenzie IF (1997) Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100: 2783-2792
25. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ (1994) Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54: 2856-2860
26. Lees CJ, Apostolopoulos V, Acres B, Ramshaw I, Ramsay A, Ong CS, McKenzie IF (2000) Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. Vaccine 19: 158-162
27. Lode HN, Xiang R, Becker JC, Gillies SD, Reisfeld RA (1998) Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol Ther 80: 277-292
28. Martoni A, Zamagni C, Bellanova B, Zanichelli L, Vecchi F, Cacciari N, Strocchi E, Pannuti F (1995) CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Eur J Cancer 31A: 1615-1621
29. Melani C, Figini M, Nicosia D, Luison E, Ramakrishna V, Casorati G, Parmiani G, Eshhar Z, Canevari S, Colombo MP (1998) Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res 58: 4146-4154
30. Morikane K, Tempero R, Sivinski CL, Kitajima S, Gendler SJ, Hollingsworth MA (2001) Influence of organ site and tumor cell type on MUC1-specific tumor immunity. Int Immunol 13: 233-240
31. Mukherjee P, Madsen CS, Ginardi AR, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ (2003) Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 26: 47-62
32. Muller S, Goletz S, Packer N, Gooley A, Lawson AM, Hanisch FG (1997) Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1. All putative sites within the tandem repeat are glycosylation targets in vivo. J Biol Chem 272: 24780-24793
33. Nakamura H, Hinoda Y, Nakagawa N, Makiguchi Y, Itoh F, Endo T, Imai K (1998) Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 33: 354-356
34. Paulsen H, Peters S, Bielfeldt T, Meldal M, Bock K (1995) Synthesis of the glycosyl amino acid N alpha-Fmoc-Ser[Ac4-beta-D-Galp-(1- > 3)-Ac2-alpha-D-GalN3p]-OPfp and N alpha-Fmoc-Thr[Ac4-beta-D-Galp-(1-> )-Ac2-alpha-D-GalN3p]-OPfp and the application in the solid-phase peptide synthesis of multiply glycosylated mucin peptides with Tn and T antigenic structures. Carbohydr Res 268: 17-34
35. Pear WS, Nolan GP, Scott ML, Baltimore D (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90: 8392-8396
36. Perkins AC, Symonds IM, Pimm MV, Price MR, Wastie ML, Symonds EM (1993) Immunoscintigraphy of ovarian carcinoma using a monoclonal antibody (111In-NCRC48) defining a polymorphic epithelial mucin (PEM) epitope. Nucl Med Commun 14: 578-586
37. Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF (2000) Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine 18: 2059-2071
38. Price MR, Briggs S, Scanlon MJ, Tendler SJB, Sibley PEC, Hand CW (1992) The mucin antigens - what are we measuring? Dis Markers 9: 205-212
39. Price MR, Hudecz F, O'Sullivan C, Baldwin RW, Edwards PM, Tendler SJ (1990) Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol Immunol 27: 795-802
40. Price MR, and 59 coathors (1997) Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumour Biol 19(Suppl): 1-20
41. Reddish M, MacLean GD, Koganty RR, Kan-Mitchell J, Jones V, Mitchell MS, Longenecker BM (1998) Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 76: 817-823
42. Rughetti A, Turchi V, Ghetti CA, Scambia G, Panici PB, Roncucci G, Mancuso S, Frati L, Nuti M (1993) Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 53: 2457-2459
43. Shu L, Qi CF, Schlom J, Kashmiri SV (1993) Secretion of a single-gene-encoded immunoglobulin from myeloma cells. Proc Natl Acad Sci USA 90: 7995-7999
44. Smith M, Burchel JM, Grahman R, Cohen EP, Taylor-Papadimitriou J (1999) Expression of B7.1 in an MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice. Immunology 97: 648-655
45. Symonds IM, Price MR, Pimm MV, Perkins AC, Wastie ML, Baldwin RW, Symonds EM (1992) Preliminary report of tumour localisaton and imaging of ovarian neoplasia with a new monoclonal antibody raised against urinary mucin. In Tumour Associated Antigens. Oncogenes, Receptors, Cytokines in Tumour Diagnosis and Therapy at the Beginning of the Ninties, Klapdor R (ed) pp 572-577. Munich: W Zuckscherdt.
46. Tempero RM, Rowse GJ, Gendler SJ, Hollingsworth MA (1999) Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice. Int J Cancer 80: 595-599
47. Tempero RM, VanLith ML, Morikane K, Rowse GJ, Gendler SJ, Hollingsworth MA (1998) CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J Immunol 161: 5500-5506
48. VanLith ML, Kohlgraf KG, Sivinski CL, Tempero RM, Hollingsworth MA (2002) MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses. Int Immunol 14: 873-882
49. Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L Jr, Hanisch FG, Finn OJ (2002) Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 196: 1435-1446.
50. Xu X, Clarke P, Szalai G, Shively JE, Williams LE, Shyr Y, Shi E, Primus FJ (2000) Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 60: 4475-4484